Phaseline

Targets › PDCD1L1

PDCD1L1 (Programmed cell death 1 ligand 1): drug programs, companies and trials

3 programs from 3 companies in 3 trials: 3 Phase 2; Oncology; next expected readout Dec 2026.

Plays a critical role in induction and maintenance of immune tolerance to self. As a ligand for the inhibitory receptor PDCD1/PD-1, modulates the activation threshold of T-cells and limits T-cell effector response. (UniProt, Q9NZQ7)

Open in Phaseline: the race on PDCD1L1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
West China HospitalTagitanlimab
Anti-PD-L1 monoclonal antibody blocking PD-1/PD-L1 signaling
PDCD1L1Phase 2Resectable Head and Neck Squamous Cell CarcinomaDec 2026
James Brugarolas89Zr-DFO-Atezolizumab
PD-L1 imaging agent (radiolabeled anti-PD-L1 antibody)
PDCD1L1Phase 2Renal Cell CarcinomaAug 2027
The First Affiliated Hospital with Nanjing Medical UniversityRetlirafusp alfa
Anti-PD-L1/TGF-β bifunctional fusion protein
PDCD1L1, TGFB1Phase 2Intrahepatic Cholangiocarcinoma (Icc)Mar 2028

Conditions

Resectable Head and Neck Squamous Cell Carcinoma (1) Renal Cell Carcinoma (1) Intrahepatic Cholangiocarcinoma (Icc) (1)

Modalities

antibody (2), small molecule (1)

Companies

West China Hospital (1) James Brugarolas (1) The First Affiliated Hospital with Nanjing Medical University (1)

Related targets

TGFB1 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.